Table 4.
Parameter | Overall Study Population | Coronary Artery Disease Group | Peripheral Arterial Disease Group | ||||||
---|---|---|---|---|---|---|---|---|---|
Beta Coefficient | SE | p | Beta Coefficient | SE | p | Beta Coefficient | SE | p | |
Coronary artery disease **§ | 131.36 | 16.52 | <0.001 | - | - | - | - | - | - |
NAFLD (US-FLI ≥ 2) ** | 34.63 | 16.44 | 0.037 | 77.77 | 42.49 | 0.075 | 10.41 | 12.47 | 0.406 |
Age * | −0.690 | 0.801 | 0.390 | −0.074 | 1.747 | 0.967 | −0.844 | 0.702 | 0.232 |
BMI * | 0.059 | 1.939 | 0.976 | - | - | - | - | - | - |
Total cholesterol * | −0.005 | 0.184 | 0.977 | - | - | - | - | - | - |
Type 2 diabetes mellitus ** | −16.43 | 16.05 | 0.308 | −25.88 | 48.75 | 0.598 | −32.80 | 13.07 | 0.014 |
Metabolic syndrome ** | - | - | - | 6.452 | 40.04 | 0.873 | 52.33 | 12.66 | <0.001 |
Model for the overall study population including coronary artery disease, NAFLD, age, BMI, total cholesterol and type 2 diabetes mellitus; model for coronary artery disease group including NAFLD, age, type 2 diabetes mellitus and metabolic syndrome; model for peripheral arterial disease including NAFLD, age, type 2 diabetes mellitus and metabolic syndrome. * per unit; ** yes vs. no; § vs. peripheral arterial disease. NAFLD: nonalcoholic fatty liver disease; US-FLI: ultrasonographic-fatty liver indicator; BMI: body mass index.